Ono Pharmaceutical Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ono Pharmaceutical Co. sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Ono Pharmaceutical Co.: 17 sponsored US clinical trials, 5 recruiting.
Ono Pharmaceutical Co. sponsors 17 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 5 completed. 3 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary CNS Lymphoma, with 1 trials.
Top-decile sponsor footprint
Ono Pharmaceutical Co. ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
17 total, page 1 of 1
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
NCT07198087
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
NCT05515406
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
A Phase 1 Study of ONO-2020 in Healthy Participants
NCT05507515
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
NCT03571594
Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors
NCT03182257
A Study of ONO-7475 in Patients With Acute Leukemias
NCT03176277
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
NCT02083289
ONO-7746 Study in Healthy Adult Subject
NCT01106664
ONO-7746 Study in Healthy Adult Subjects
NCT00956371
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Ono Pharmaceutical Co. pipeline
5 recruiting of 17 indexed (29% open); 5 completed (29%).
Phase mix: 3 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Primary CNS Lymphoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ono Pharmaceutical Co.: open-pipeline peers nationwide
Peers matched on 17 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Ono Pharmaceutical Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Children's Hospital Los Angeles · 29% recruiting · 119 trials
- Natural Immune Systems · 29% recruiting · 17 trials
- Queen's Medical Center · 29% recruiting · 17 trials
- Inova Health Care Services · 29% recruiting · 75 trials
Related
What to do with this Ono Pharmaceutical Co. page
17 registered trials is a research-attention snapshot, not an endorsement of Ono Pharmaceutical Co. or any single study.
- 5 of Ono Pharmaceutical Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary CNS Lymphoma is the condition Ono Pharmaceutical Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary CNS Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ono Pharmaceutical Co. pipeline card: 17 registered trials from official public datasets.Report a data error.